Action Alto Neuroscience - ANRO

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

3,8996

Prix Achat

Prix Vente

Volume échangé

595 323

3,20 Fourchette du Jour 3,95

2,67 Plage de 52 semaines 18,3499

Cap du marché

105,173M

Clôture Veille

3,38

Ouverture

3,34

Dernière Transaction

3.8891

Dernière heure de transaction

Volume financier

US$ 2 123 767

VWAP

3,5674

Volume moyen (3 m)

309 187

Actions en circulation

26 970 168

Rendement du Dividende

Ratio Cours sur Bénéfices

-2,93

Bénéfice par action (BPA)

-1,35

Chiffre d'affairess

Bénéfice net

-36,31M

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients' b... Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients' brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates. Show more

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.altoneuroscience.com

Siège social

Wilmington, Delaware, USA

Fondé

Alto Neuroscience Inc est coté dans le secteur Pharmaceutical Preparations de la New York Stock Exchange avec le ticker ANRO. Le dernier cours de clôture d'Alto Neuroscience était de US$3,38. Au cours de la dernière année, les actions de Alto Neuroscience ont été négociées dans une fourchette de prix de US$ 2,67 à US$ 18,3499.

Alto Neuroscience compte actuellement 26 970 168 actions en circulation. La capitalisation boursière d'Alto Neuroscience est de US$91,16 million. Alto Neuroscience a un ratio cours/bénéfice (ratio PE) de -2.93.

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

– Patent supports Alto’s precision approach to improve patient selection – Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.9496	32.1898305085	2.95	3.96	2.67	887013	3.15085818	CS
4	-0.3504	-8.24470588235	4.25	4.25	2.67	420106	3.18448753	CS
12	0.0596	1.55208333333	3.84	4.88	2.67	309187	3.70569993	CS
26	-8.8204	-69.3427672956	12.72	15.04	2.67	560336	6.25512797	CS
52	-12.3004	-75.9283950617	16.2	18.3499	2.67	359803	7.78528098	CS
156	-18.1004	-82.2745454545	22	24	2.67	357032	8.48009847	CS
260	-18.1004	-82.2745454545	22	24	2.67	357032	8.48009847	CS

ANRO - Frequently Asked Questions (FAQ)

What is the current Alto Neuroscience share price?

The current share price of Alto Neuroscience is US$ 3,8996

How many Alto Neuroscience shares are in issue?

Alto Neuroscience has 26 970 168 shares in issue

What is the market cap of Alto Neuroscience?

The market capitalisation of Alto Neuroscience is USD 91,16M

What is the 1 year trading range for Alto Neuroscience share price?

Alto Neuroscience has traded in the range of US$ 2,67 to US$ 18,3499 during the past year

What is the PE ratio of Alto Neuroscience?

The price to earnings ratio of Alto Neuroscience is -2,93

What is the reporting currency for Alto Neuroscience?

Alto Neuroscience reports financial results in USD

What is the latest annual profit for Alto Neuroscience?

The latest annual profit of Alto Neuroscience is USD -36,31M

What is the registered address of Alto Neuroscience?

The registered address for Alto Neuroscience is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Alto Neuroscience website address?

The website address for Alto Neuroscience is www.altoneuroscience.com

Which industry sector does Alto Neuroscience operate in?

Alto Neuroscience operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MYEMyers Industries Inc	US$ 12,4895 (28,23%)	1,38M
SUPSuperior Industries International	US$ 2,01 (20,36%)	463,05k
MSCStudio City International Holdings Limited	US$ 3,30 (19,57%)	28,56k
SSTSystem1 Inc	US$ 0,5602 (19,22%)	189,66k
ANROAlto Neuroscience Inc	US$ 3,94 (16,57%)	595,23k
PNSTPinstripes Holdings Inc	US$ 0,0473 (-69,29%)	1,31M
VGVenture Global Inc	US$ 9,10 (-36,05%)	44,43M
ONLOrion Office REIT Inc	US$ 2,7195 (-29,36%)	3,99M
MEIMethode Electronics Inc	US$ 7,00 (-28,72%)	1,56M
BKSYBlackSky Technology Inc	US$ 9,98 (-24,39%)	3,85M
FFord Motor Company	US$ 9,61 (-0,41%)	136,68M
BTEBaytex Energy Corporation	US$ 1,98 (0,00%)	69,22M
NUNu Holdings Ltd	US$ 10,65 (-2,02%)	64,37M
BACBank of America Corporation	US$ 41,46 (-1,96%)	58,12M
BBAIBigBear ai Holdings Inc	US$ 4,225 (-11,98%)	55,67M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Alto Neuroscience Inc (ANRO) Cours

Alto Neuroscience Inc (ANRO)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Alto Neuroscience Inc

ANRO Dernières nouvelles

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Form 8-K - Current report

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Form EFFECT - Notice of Effectiveness

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Form 8-K - Current report

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Form EFFECT - Notice of Effectiveness

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

ANRO - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités